Rakovina Therapeutics’ focus is the development of new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics fromHealth Canada, the United States Food and Drug Administration and similar international regulatory agencies

Biotechnology

Rakovina Therapeutics Inc.

Rakovina Therapeutics Inc.'s headquarters in Vancouver, Canada

Description

People (1)

Michelle Seltenrich

Jobs